Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Astellas Venture Management
Deal Size : $46.0 million
Deal Type : Series A Financing
Mogrify Extends Series A Financing to $46 Million USD
Details : The financing will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Astellas Venture Management
Deal Size : $46.0 million
Deal Type : Series A Financing
Lead Product(s) : AAV-Based Genetic Medicine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the collaboration, Astellas Gene Therapies, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus based genetic medicine and translational capabilities to complete experiments in pre-clinical...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 05, 2022
Lead Product(s) : AAV-Based Genetic Medicine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CAR-Treg cell therapy
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Sangamo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sangamo taps Mogrify for off-the-shelf CAR-Treg project
Details : Mogrify will discover and optimize cell conversion technology from iPSCs or ESCs to regulatory T cells. Sangamo will use Mogrify’s technology to create Tregs from iPSCs or ESCs.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 21, 2020
Lead Product(s) : CAR-Treg cell therapy
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Sangamo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?